Application of peptide-based prodrug chemistry in drug development
https://libcat.nshealth.ca/en/permalink/provcat32406
Arnab De, author ; with special thanks to Richard DiMarchi and the Linda & Jack Gill Chair in Biomolecular Sciences at Indiana University ; with foreword by Jean Martinez.
--New York, NY:
Springer
, c2013.
- Available Online
- View e-Book
- Location
- Online
- Available Online
- View e-Book
- Author
- De, Arnab
- Responsibility
- Arnab De, author ; with special thanks to Richard DiMarchi and the Linda & Jack Gill Chair in Biomolecular Sciences at Indiana University ; with foreword by Jean Martinez
- Place of Publication
- New York, NY
- Publisher
- Springer
- Date of Publication
- c2013
- ISBN
- 9781461448754
- Subjects (MeSH)
- Drug Design
- Peptides - pharmacology
- Prodrugs
- Subjects (LCSH)
- Toxicology
- Pharmaceutical technology
- Diabetes
- Contents
- Introduction -- Application of prodrug chemistry to GLP-1 -- Experimental procedures -- Characterization of prodrugs -- Conclusion -- Appendix I: Schematic Synthesis of Longer Acting Prodrugs -- Appendix II: Structure of Peptides in Table A.1 -- Appendix III: Structure of Peptides in Table A.2 -- Appendix IV: Structure of Peptides in Table A.3 -- Appendix V: Structure of Peptides in Table A.4 -- Appendix VI: Structure of Peptides in Table A.5 -- Appendix VII: Structure of Peptides in Table A.6 -- Appendix VIII: Acylation of HO-His7, GLP(8–37) -- Appendix IX: A Note on Nomenclature.
- Format
- e-Book
- Location
- Online
Big Data in Healthcare : Extracting Knowledge from Point-of-Care Machines
https://libcat.nshealth.ca/en/permalink/provcat41863
Pouria Amirian, Trudie Lang, Francois van Loggerenberg, editors.
--Cham:
Springer
, 2017.
- Available Online
- View e-Book
- Location
- Online
This book reviews a number of issues including: Why data generated from POC machines are considered as Big Data. What are the challenges in storing, managing, extracting knowledge from data from POC devices? Why is it inefficient to use traditional data analysis with big data? What are the solutions for the mentioned issues and challenges? What type of analytics skills are required in health care? What big data technologies and tools can be used efficiently with data generated from POC devices?…
- Available Online
- View e-Book
- Other Authors
- Amirian, Pouria
- Lang, Trudie
- van Loggerenberg, Francois
- Responsibility
- Pouria Amirian, Trudie Lang, Francois van Loggerenberg, editors
- Place of Publication
- Cham
- Publisher
- Springer
- Date of Publication
- 2017
- Physical Description
- 1 online resource (vii, 100 pages) : 46 illus., 45 illus. in color
- ISBN
- 9783319629902
- 9783319629889 (print ed.)
- ISSN
- 1864-8118
- Subjects (MeSH)
- Data Mining
- Health Planning
- Internet
- Medical Informatics
- Point-of-Care Systems
- Telemedicine
- Telemetry
- Abstract
- This book reviews a number of issues including: Why data generated from POC machines are considered as Big Data. What are the challenges in storing, managing, extracting knowledge from data from POC devices? Why is it inefficient to use traditional data analysis with big data? What are the solutions for the mentioned issues and challenges? What type of analytics skills are required in health care? What big data technologies and tools can be used efficiently with data generated from POC devices? This book shows how it is feasible to store vast numbers of anonymous data and ask highly specific questions that can be performed in real-time to give precise and meaningful evidence to guide public health policy.
- Contents
- Introduction: Improving Healthcare with Big Data -- Data Science and Analytics -- Big Data and Big Data Technologies -- Big Data Analytics for Extracting Disease Surveillance Information: An Untapped Opportunity -- Ebola and Twitter. What Insights Can Public Health Draw from Social Media?
- Format
- e-Book
- Location
- Online
Extremophilic Cyanobacteria For Novel Drug Development
https://libcat.nshealth.ca/en/permalink/provcat39132
Sikha Mandal, Jnanendra Rath.
--Cham:
Springer
, c2015.
- Available Online
- View e-Book
- Location
- Online
This volume presents recent developments in the novel drug development and potential of extremophilic cyanobacteria. It discusses how these tiny organism originated, produce oxygen that leads to evolution of life on the earth, how their survival strategies in extreme climatic conditions lead to diverse metabolic pathways, and the opportunity to use them to develop novel drugs. The book is comprised of five chapters, starting with the origin of cyanobacteria, their survival strategies under extr…
- Available Online
- View e-Book
- Author
- Mandal, Sikha
- Other Authors
- Rath, Jnanendra
- Responsibility
- Sikha Mandal, Jnanendra Rath
- Place of Publication
- Cham
- Publisher
- Springer
- Date of Publication
- c2015
- Physical Description
- 1 online resource (vii, 92 p. : 1 illus.)
- ISBN
- 9783319120096
- 9783319120089 (print ed.)
- ISSN
- 1864-8118
- Subjects (MeSH)
- Cyanobacteria - chemistry
- Drug Discovery
- Abstract
- This volume presents recent developments in the novel drug development and potential of extremophilic cyanobacteria. It discusses how these tiny organism originated, produce oxygen that leads to evolution of life on the earth, how their survival strategies in extreme climatic conditions lead to diverse metabolic pathways, and the opportunity to use them to develop novel drugs. The book is comprised of five chapters, starting with the origin of cyanobacteria, their survival strategies under extreme conditions, and their capabilities to change metabolic activities.The second chapter explores the different metabolic pathways found in cyanobacteria and examines advances in this field and recent techniques like MALDI-TOF imaging and metagenomics tools as well as in silico techniques for rapid screening of secondary metabolites. Further chapters cover the glycomics of cyanobacteria, anticancer drug development, and some issues and challenges of using cyanobacteria to develop drugs. Extremophilic Cyanobacteria For Novel Drug Development provides insight into future perspectives in drug development and is a key resource for students, researchers and professionals in pharmacy, medicinal chemistry, pharmacognosy biotechnology, biology, and academics.
- Contents
- 1. Introduction -- 2. Secondary Metabolites of Cyanobacteria and Drug Development -- 3. Glycoconjugates of Cyanobacteria and Potential Drug Development from them -- 4. Anticancer Drug Development from Cyanobacteria -- 5. Issues and Challenges of Drug Development from Cyanobacteria.
- Format
- e-Book
- Location
- Online
Lipid Nanoparticles : Production, Characterization and Stability
https://libcat.nshealth.ca/en/permalink/provcat39117
Rohan Shah, Daniel Eldridge, Enzo Palombo, Ian Harding.
--Cham:
Springer
, c2015.
- Available Online
- View e-Book
- Location
- Online
What are lipid nanoparticles? How are they structured? How are they formed? What techniques are best to characterize them? How great is their potential as drug delivery systems? These questions and more are answered in this comprehensive and highly readable work on lipid nanoparticles. This work sets out to provide the reader with a clear and understandable understanding of the current practices in formulation, characterization and drug delivery of lipid nanoparticles. A comprehensive descripti…
- Available Online
- View e-Book
- Author
- Shah, Rohan
- Other Authors
- Eldridge, Daniel
- Palombo, Enzo
- Harding, Ian
- Responsibility
- Rohan Shah, Daniel Eldridge, Enzo Palombo, Ian Harding
- Place of Publication
- Cham
- Publisher
- Springer
- Date of Publication
- c2015
- Physical Description
- 1 online resource (ix, 97 p. : 30 illus., 18 illus. in color)
- ISBN
- 9783319107110
- 9783319107103 (print ed.)
- ISSN
- 1864-8118
- Subjects (MeSH)
- Biomedical Engineering
- Lipids
- Nanoparticles
- Nanotechnology
- Abstract
- What are lipid nanoparticles? How are they structured? How are they formed? What techniques are best to characterize them? How great is their potential as drug delivery systems? These questions and more are answered in this comprehensive and highly readable work on lipid nanoparticles. This work sets out to provide the reader with a clear and understandable understanding of the current practices in formulation, characterization and drug delivery of lipid nanoparticles. A comprehensive description of the current understanding of synthesis, characterization, stability optimization and drug incorporation of solid lipid nanoparticles is provided. Nanoparticles have attracted great interest over the past few decades with almost exponential growth in their research and application. Their small particle size and subsequent high surface area make them ideal in many uses, but particularly as drug carrier systems. Nanoparticles made from lipids are especially attractive because of their enhanced biocompatibility imparted by the lipid. The work provides a detailed description of the types of lipid nanoparticles available (e.g. SLN, NLC, LDC, PLN) and how they range from imperfect crystalline to amorphous in structure. Current thoughts on where drugs are situated (e.g. in the core, or at the interface) and how this can be manipulated are discussed. The many techniques for production, including the author's own variant of microwave heating, are fully discussed. Techniques for measuring arguably the most important characteristics of particle size and polydispersity are discussed, along with techniques to measure crystallinity, shape and drug capacity. Finally, a full chapter on techniques for measuring stability, both in the absence and presence of drugs, is discussed, along with suggestions on how to optimize that stability. This work appeals to students of colloid science, practitioners of research into drug delivery and academics alike.
- Contents
- Introduction -- Composition and structure -- Production techniques -- Characterization -- Physicochemical stability.
- Format
- e-Book
- Location
- Online
Mid-size Drugs Based on Peptides and Peptidomimetics : A New Drug Category
https://libcat.nshealth.ca/en/permalink/provcat42862
Hirokazu Tamamura, Takuya Kobayakawa, Nami Ohashi.
--Singapore:
Springer
, c2018.
- Available Online
- View e-Book
- Location
- Online
This brief describes studies conducted by the authors on mid-size drugs utilizing peptides and peptidomimetics, and on the development of anti-HIV agents. Peptides are important biological molecules and have various physiological actions. Peptide-based drug discovery may help bring about the development of useful medicines that are highly safe and show potent pharmacological effects in small doses. Recently, it has been shown that there is an important drug-like space in the mid-sized region be…
- Available Online
- View e-Book
- Author
- Tamamura, Hirokazu
- Other Authors
- Kobayakawa, Takuya
- Ohashi, Nami
- Responsibility
- Hirokazu Tamamura, Takuya Kobayakawa, Nami Ohashi
- Place of Publication
- Singapore
- Publisher
- Springer
- Date of Publication
- c2018
- Physical Description
- 1 online resource (xvii, 100 p.) : 40 illus., 32 illus. in color
- ISBN
- 9789811076916
- 9789811076909 (print ed.)
- 9789811076923 (print ed.)
- ISSN
- 1864-8118
- Subjects (MeSH)
- Anti-HIV Agents - pharmacology
- Drug Design
- Peptides - chemistry
- Peptides - pharmacology
- Peptidomimetics - chemistry
- Peptidomimetics - pharmacology
- Specialty
- Pharmacology
- Abstract
- This brief describes studies conducted by the authors on mid-size drugs utilizing peptides and peptidomimetics, and on the development of anti-HIV agents. Peptides are important biological molecules and have various physiological actions. Peptide-based drug discovery may help bring about the development of useful medicines that are highly safe and show potent pharmacological effects in small doses. Recently, it has been shown that there is an important drug-like space in the mid-sized region between low- and high-molecular-weight compounds. Thus, mid-size drugs such as peptide compounds are being focused on. To date, several peptidomimetics that mimic primary, secondary, and tertiary structures of peptides have been developed to maintain and improve biological activities and actions of peptides. In this book, the features and advantages of mid-size drugs are described in detail. In addition, the merits of utilizing peptidomimetics in the development of mid-size drugs are referred to. Understanding such peptide-derived mid-size drugs will lead to a comprehensive expansion of medicinal chemistry.
- Contents
- 1. Introduction of Mid-Size Drugs and Peptidomimetics -- 2. Chloroalkene Dipeptide Isosteres as Peptidomimetics -- 3. Conformational-restricted Cyclic Peptides -- 4. Peptidomimetics that Mimic Secondary Structures of Peptides -- 5.Peptidomimetics that Mimic Tertiary Structures of Peptides -- 6. Conjugated Compounds Involving Peptides -- 7. Summary and Future Perspectives of Researches on Mid-Size Drugs.
- Format
- e-Book
- Location
- Online
New Approaches to Natural Anticancer Drugs
https://libcat.nshealth.ca/en/permalink/provcat39179
Soodabeh Saeidnia.
--Cham:
Springer
, c2015.
- Available Online
- View e-Book
- Location
- Online
This book provides an up-to-date review of recently identified natural anti-tumor compounds from various natural origins including plants, fungi, endophytic fungi and marine organisms. It also includes discussion of new areas such as biotechnology and nanoparticles. Chapters explain the challenges and developments in anti-cancer drug discovery approaches, traditional remedies for prevention and treatment of cancer, marine-derived anti-cancer compounds, and antibiotics used as anti-cancer agents…
- Available Online
- View e-Book
- Author
- Saeidnia, Soodabeh
- Responsibility
- Soodabeh Saeidnia
- Place of Publication
- Cham
- Publisher
- Springer
- Date of Publication
- c2015
- Physical Description
- 1 online resource (xi, 106 p. : 28 illus., 6 illus. in color)
- ISBN
- 9783319140278
- 9783319140261 (print ed.)
- ISSN
- 1864-8118
- Subjects (MeSH)
- Antineoplastic Agents
- Drug Discovery
- Plants, Medicinal
- Abstract
- This book provides an up-to-date review of recently identified natural anti-tumor compounds from various natural origins including plants, fungi, endophytic fungi and marine organisms. It also includes discussion of new areas such as biotechnology and nanoparticles. Chapters explain the challenges and developments in anti-cancer drug discovery approaches, traditional remedies for prevention and treatment of cancer, marine-derived anti-cancer compounds, and antibiotics used as anti-cancer agents, as well as different classes of terpenoids and carbohydrates, which have been the subject of discussion in this field as efficient anti-cancer candidates. This book will be a concise guide for researchers in the field of pharmaceutical sciences, students and residents in pharmacy and medicine as well as those researching phytochemistry and natural products.
- Contents
- Anticancer drug discovery approaches: challenges and development -- An Evidence Based Approach to Traditional Herbal Remedies for the Management of Cancer -- Marine-derived Anticancer Compounds -- Anti-cancer Antibiotics -- Anticancer Terpenoids -- Carbohydrates Against Cancer.
- Format
- e-Book
- Location
- Online
Pharmaceutical Competitive Intelligence for the Regulatory Affairs Professional
https://libcat.nshealth.ca/en/permalink/provcat30981
Raymond A. Huml.
--New York, NY:
Springer
, c2012.
- Available Online
- View e-Book
- Location
- Online
This Brief defines competitive intelligence (CI) as a tool for making investment decisions within the pharmaceutical industry.It provides an overview of processes that the regulatory affairs professional must take into account when evaluating data impacting product-based risk evaluations. These apply particularly to evaluations that focus on outputs such as regulatory approval, or the commercial impact of product labeling on the sales forecast over a limited timeframe. The Brief also provides a…
- Available Online
- View e-Book
- Author
- Huml, Raymond A
- Responsibility
- Raymond A. Huml
- Place of Publication
- New York, NY
- Publisher
- Springer
- Date of Publication
- c2012
- Physical Description
- 1 online resource (xv, 82 p. : 4 ill., 3 ill. in color)
- ISBN
- 9781461436829
- Subjects (MeSH)
- Drug Approval - United States
- Drug Industry - legislation & jurisprudence - United States
- Economic Competition
- Pharmacovigilance
- Subjects (LCSH)
- Pharmaceutical technology
- Abstract
- This Brief defines competitive intelligence (CI) as a tool for making investment decisions within the pharmaceutical industry.It provides an overview of processes that the regulatory affairs professional must take into account when evaluating data impacting product-based risk evaluations. These apply particularly to evaluations that focus on outputs such as regulatory approval, or the commercial impact of product labeling on the sales forecast over a limited timeframe. The Brief also provides an overview of intellectual property assessment that can impact a product's lifespan on the market due to patent protection itself (or loss of patent protection) or via regulatory exclusivity. Case examples are discussed to illustrate the importance of keeping up with the ever-changing regulations, and how to interpret them in the context of CI. In addition, there is a section on virtual data rooms (VDRs) which currently function as the cornerstone of due diligence investigations. While aimed primarily at regulatory affairs professionals in the United States, this publication provides a useful adjunct for other pharmaceutical executives, especially those new to product-based investments, and regulatory affairs professionals in other regions.
- Contents
- Introduction to Competitive Intelligence -- Overall Perspective of Due Diligence Investigations and Processes -- The Regulatory Functional Review: Primary Roles -- The On-Site Due Diligence/Data Room Meeting and Interactions with other Functional Area Experts -- Intellectual Property -- The Final Report -- Competitive Intelligence Summary.
- Format
- e-Book
- Location
- Online
Pharmacological potential of selected natural compounds in the control of parasitic diseases
https://libcat.nshealth.ca/en/permalink/provcat32522
Gabriela Hrckova, Samuel Velebny, authors.
--Vienna:
Springer
, c2013.
- Available Online
- View e-Book
- Location
- Online
The natural world with a large number of terrestrial and marine plants and lower organisms is a great source of bioactive compounds historically used as remedies in various diseases. Within the last decade, such compounds became more attractive targets for pharmacologists and the pharmaceutical industry in drug development projects. This volume presents the pharmacological potential of chemically defined natural compounds obtained from plants, fungi, algae and cyanobacteria with antiparasitic a…
- Available Online
- View e-Book
- Author
- Hrckova, Gabriela
- Other Authors
- Velebny, Samuel
- Responsibility
- Gabriela Hrckova, Samuel Velebny, authors
- Place of Publication
- Vienna
- Publisher
- Springer
- Date of Publication
- c2013
- Physical Description
- 1 online resource (xi, 125 p. : 19 ill., 8 ill. in color)
- ISBN
- 9783709113257
- Subjects (MeSH)
- Antiparasitic Agents - therapeutic use
- Biological Agents - pharmacology
- Biological Agents - therapeutic use
- Parasitic Diseases - drug therapy
- Subjects (LCSH)
- Parasitology
- Toxicology
- Abstract
- The natural world with a large number of terrestrial and marine plants and lower organisms is a great source of bioactive compounds historically used as remedies in various diseases. Within the last decade, such compounds became more attractive targets for pharmacologists and the pharmaceutical industry in drug development projects. This volume presents the pharmacological potential of chemically defined natural compounds obtained from plants, fungi, algae and cyanobacteria with antiparasitic activity, that have been tested against various endo-parasitic protozoan and helminth species. Additionally, the advantages of combined therapy using antiparasitic drugs and natural compounds with selected specific activity are reviewed and explained in the context of host pathology and immunosuppression induced by the parasites. The conclusions of this new book give suggestions for further non-empirical drug development and discuss perspectives of alternative approaches to therapy of parasitic diseases.
- Contents
- Protozoan infections, pathology and therapy -- Current antiprotozoan drugs and problem of resistance -- Natural compounds with direct antiprotozoal activity -- Natural compounds isolated from higher plants -- Bioactive compounds from lower terrestrial organisms -- Marine organisms undiscovered source of the potential drugs -- Concluding remarks -- Parasitic helminthes of human and amimals: health impact and control -- Anthelmintic drugs efficacy, side effects and resistance -- Natural compounds with direct anthelmintic activity -- Anthelmintic potential of higher plants -- Lower terrestrial and marine organisms in anthelmintic drug discovery -- Concluding remarks -- Combined therapy of parasitic infections using substances from natural sources -- Host pathology and immunosuppression during parasitic infections -- Natural compounds with immunomodulatory effects -- Natural compounds with antioxidant and other host-protecting activities -- Summary: perpectives and possibilities in drug discovery from natural sources.
- Format
- e-Book
- Location
- Online
A practical guide to drug development in academia : the SPARK approach
https://libcat.nshealth.ca/en/permalink/provcat33397
Daria Mochly-Rosen, Kevin Grimes, editors.
--Cham, Switzerland:
Springer
, c2014.
- Available Online
- View e-Book
- Location
- Online
Written by the founders of the SPARK program at Stanford University, this book is a practical guide designed for professors, students and clinicians at academic research institutions who are interested in learning more about the drug development process and how to help their discoveries become the novel drugs of the future. Often many potentially transformative basic science discoveries are not pursued because they are deemed "too early" to attract industry interest. There are simple, relativel…
- Available Online
- View e-Book
- Other Authors
- Mochly-Rosen, Daria
- Grimes, Kevin D
- Responsibility
- Daria Mochly-Rosen, Kevin Grimes, editors
- Place of Publication
- Cham, Switzerland
- Publisher
- Springer
- Date of Publication
- c2014
- Physical Description
- 1 online resource (xii, 176 pages)
- ISBN
- 9783319022017 (electronic bk.)
- 9783319022000
- Subjects (MeSH)
- Drug Discovery - methods
- Drug Evaluation - methods
- Drug Industry
- Translational Medical Research - organization & administration
- Subjects (LCSH)
- Drug development - Handbooks, manuals, etc
- Drugs - Design - Handbooks, manuals, etc
- Drug Discovery - Handbooks
- Drug Design - Handbooks
- Abstract
- Written by the founders of the SPARK program at Stanford University, this book is a practical guide designed for professors, students and clinicians at academic research institutions who are interested in learning more about the drug development process and how to help their discoveries become the novel drugs of the future. Often many potentially transformative basic science discoveries are not pursued because they are deemed "too early" to attract industry interest. There are simple, relatively cost-effective things that academic researchers can do to advance their findings to the point that they can be tested in the clinic or attract more industry interest.
- Contents
- Getting started -- Discovery and preclinical work -- Preparing for the clinic -- Transferring technology -- Commercialization and entrepreneurship -- Concluding thoughts.
- Format
- e-Book
- Location
- Online
Systems biology in biotech & pharma : a changing paradigm
https://libcat.nshealth.ca/en/permalink/provcat31279
Aleš Prokop, Seth Michelson, authors.
--Dordrecht:
Springer
, c2012.
- Available Online
- View e-Book
- Location
- Online
Systems Biology (SB) is a suite of technologies and methodologies that resulted, conceptually from the merging of two basic paradigms, reductionism and holism. It represents a combination of reductionist and holistic approaches to the relationships among the elements of a system, with the goal of identifying its emergent properties and defining, quantitatively, molecular, cellular, tissue, organ and whole body processes. One manifestation of SB is as a tool for hypothesis generation about a sys…
- Available Online
- View e-Book
- Author
- Prokop, Aleš
- Other Authors
- Michelson, Seth
- Responsibility
- Aleš Prokop, Seth Michelson, authors
- Place of Publication
- Dordrecht
- Publisher
- Springer
- Date of Publication
- c2012
- Physical Description
- 1 online resource (xviii, 127 p. : 16 ill. in color)
- ISBN
- 9789400728493
- Subjects (MeSH)
- Biotechnology
- Chemistry, Pharmaceutical
- Computational Biology
- Systems Biology
- Subjects (LCSH)
- Pharmaceutical technology
- Biotechnology
- Microbiology
- Abstract
- Systems Biology (SB) is a suite of technologies and methodologies that resulted, conceptually from the merging of two basic paradigms, reductionism and holism. It represents a combination of reductionist and holistic approaches to the relationships among the elements of a system, with the goal of identifying its emergent properties and defining, quantitatively, molecular, cellular, tissue, organ and whole body processes. One manifestation of SB is as a tool for hypothesis generation about a system that is typically too large and complex to understand by simple reasoning.
- Contents
- Abstract -- 1. Introduction: Discovery & Development - New Facet Of Industry, New Tools And Lead Optimization: 1.1. Scope And Content Of This Review -- 2. Discovery: Use Of Systems Biology For Identifying Targets -- 3. Integrative Systems Biology I - Biochemistry: Phase I Lead Discovery & Molecular Interactions -- 4. Integrative Systems Biology Ii - Molecular Biology: Phase 2 Lead Discovery & In Silico Screening -- 5. Discovery: Computational Systems Biology (Csb) In Health & And Disease I -- 6. Development: In Vivo Pharmacology - Systems Biology In Health & Disease Ii -- 7. Development: Pharmacokinetics Systems Biology In Health & Disease Iii -- 8. Development: Multiscale Csb Simulation Tools -- 9. Development: Drug Formulation & Delivery -- 10. Development: Preclinical Model Based Drug Development -- 11. Systems Biology: Impact On Pharma And Biotech -- 12. Acknowledgment -- 13. Bibliography.
- Format
- e-Book
- Location
- Online
